Back to Authors

Jacobs, Michael A.

https://orcid.org/0000-0002-1125-1644

Mayo Clinic

Johns Hopkins University

Citations 2

A Multidimensional Connectomics- and Radiomics-Based Advanced Machine-Learning Framework to Distinguish Radiation Necrosis from True Progression in Brain Metastases
Cao, Yilin , Parekh, Vishwa S. , Chen, Xuguang , Pillai, Jay J. , Peng, Luke , Jacobs, Michael A. , Kleinberg, Lawrence , Chen, Xuguang , Pillai, Jay J , Jacobs, Michael A , Kleinberg, Lawrence R , Lee, Emerson E. , Redmond, Kristin Janson

Cancers | August 15, 2023 | Volume: 15 | Issue: 16 | Pages: 4113

10.3390/cancers15164113 Get It

We introduce tumor connectomics, a novel MRI-based complex graph theory framework that describes the intricate network of relationships within the tumor and surrounding tissue, and combine this with multiparametric radiomics (mpRad) in a machine-learning approach to distinguish radiation necrosis (RN) from true progression (TP). Pathologically confirmed cases of RN vs. TP in brain metastases treated with SRS were included from a single institution. The region of interest was manually segmented as the single largest diameter of the T1 post-contrast (T1C) lesion plus the corresponding area of T2 FLAIR hyperintensity. There were 40 mpRad features and 6 connectomics features extracted, as well as 5 clinical and treatment factors. We developed an Integrated Radiomics Informatics System (IRIS) based on an Isomap support vector machine (IsoSVM) model to distinguish TP from RN using leave-one-out cross-validation. Class imbalance was resolved with differential misclassification weighting during model training using the IRIS. In total, 135 lesions in 110 patients were analyzed, including 43 cases (31.9%) of pathologically proven RN and 92 cases (68.1%) of TP. The top-performing connectomics features were three centrality measures of degree, betweenness, and eigenvector centralities. Combining these with the 10 top-performing mpRad features, an optimized IsoSVM model was able to produce a sensitivity of 0.87, specificity of 0.84, AUC-ROC of 0.89 (95% CI: 0.82–0.94), and AUC-PR of 0.94 (95% CI: 0.87–0.97).
Letter to Cancer Center Directors: Progress in Quantitative Imaging As a Means to Predict and/or Measure Tumor Response in Cancer Therapy Trials
Mountz, James M. , Yankeelov, Thomas E. , Buatti, John M. , Erikson, B., Fennessy, Fiona M., Gillies, Robert J. , Huang, Wie, Jacobs, Michael A. , Kinahan, Paul E. , Laymon, Charles M. , Mankoff, David A. , Schwartz, Lawrence H., Shim, Hyunsuk , Wahl, Richard L. , Erikson, Bradley J, Rubin, Daniel L. , Linden, Hannah M. , Buatti, John M , Wahl, Richard L , Jacobs, Michael A , Mankoff, David A

Journal of Clinical Oncology | May 28, 2014 | Volume: 32 | Issue: 19 | Pages: 2115-2116

10.1200/jco.2014.55.8866 Get It